Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys Expanded Access in Chronic Hepatitis B
NCT02791269Phase 4Completed
- Sponsor
- Roche
- Start
- Jan 2006
- Primary completion
- Jul 2008
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) (2 arms), sponsored by Roche. Primary endpoints: Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter at Week 72 and Number of Participants With HBV-DNA <20,000 Copies/mL at Week 72. Started Jan 2006; status: completed.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02791269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791269.